FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
nours per response	e 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)																			
1. Name and Address of Reporting Person * MCGRATH JOHN				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]									5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 02/21/2017)		Director	er (give title bel	ow) Chief Financ	10% Own Other (sp	ecify bel	ow)	
(Street) SOUTH SAN FRANCISCO, CA 94080				1	4. If Amendment, Date Original Filed(Month/Day/Year)							ear)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person								
												-	Form filed by More than One Reporting Person								
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui										d, Disp	osed of, or	Beneficially	Owne	i		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			2A. Deemed Execution Date, if any (Month/Day/Year		,	Code (Inst	e	etion V	O		sposed of (D)		D) Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				rship of E	. Nature f Indirect geneficial ownership Instr. 4)			
Common	Stock		02/21/20	017					(1)	v	9,000	D	\$ 15.1 (2)					(Instr.	4)		
indirectly.	•	separate line f								Pers cont the	sons wh tained i form dis	n this splays	form a cu	are i	not req tly valid	uired to re d OMB co	nformation espond un ntrol numb	less	SEC	C 1474 (9- 02)	
			Т	able II - I							isposed (, conver				Owned	l					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	Year) Ex	Deemed ecution Da	4. Transacti Code Year) (Instr. 8)		tion			6. Date Exercisabl and Expiration Da		cisable on Dat	e // (7. Titl Amou Under Securi	lying		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For De Sec Dir or I	nershi m of		
						Code	V	(A)	(D)	Dat Exe		Expira Date	ution	Γitle	Amount or Number of Shares						
Repor	ting O	wners					•			•				·							
D	utina O	v Name / A 3	Iwana					Relat	ionsh	ips											
Reporting Owner Name / Address Director			r 10% Owner Officer								(Other									
MCGRATH JOHN 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080				EVP & Chief Financial Officer						cer											

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for John F. McGrath, Jr.	02/22/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- (2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$14.90 to \$15.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.